AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung

Roche

Status: Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01827852

ML28306

Details and patient eligibility

About

This prospective observational study will evaluate the efficacy and safety of first-line Avastin (bevacizumab) in combination with platinum-based chemotherapy in different age groups (<60, 60-69, 70-79, >80 years) in patients with inoperable advanced, metastatic or recurrent adenocarcinoma non-small cell lung cancer. Patients will be followed for 18 months from the start of first-line therapy.

Enrollment: 1,107 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/= 18 years of age
• Histologically confirmed inoperable advanced, metastatic or recurrent pre-dominantly non-squamous adenocarcinoma non-small cell lung cancer

Exclusion criteria

• Contraindications to Avastin treatment according to the Summary of Product Characteristics

Trial design

1,107 participants in 1 patient group

Cohort